Type 2 Diabetes Mellitus (T2DM) and hypertension stand as leading causes of morbidity and mortality in the Middle East, a fact that underscores the urgent need for comprehensive strategies to combat these chronic conditions. This digest provides an overview of the pivotal review titled “Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit,” published in Advances in Therapy. The review synthesizes the outcomes of the EVIDENT Summit of 2022, offering a critical examination of the current state of T2DM and hypertension management within the Middle East. It highlights the essential role of personalized treatment approaches, evaluates the efficacy of oral glucose-lowering and antihypertensive agents, and examines the influence of patient, physician, cultural, and governmental factors on disease management. Moreover, it presents targeted recommendations aimed at improving disease prevention, increasing awareness among the public and healthcare providers, and encouraging the implementation of effective government policies and research initiatives. Through this digest, we aim to succinctly summarize the key findings and recommendations outlined in the review, highlighting the imperative for coordinated efforts to enhance the care and outcomes for individuals with T2DM and hypertension in the Middle East.